论文部分内容阅读
目的探讨达比加群酯在阵发性心房颤动(简称房颤)射频消融术后抗凝治疗的安全性。方法将60例阵发性房颤射频消融术后患者,随机分为达比加群酯组(30例)和华法林组(30例),观察两组患者射频消融术后抗凝治疗的安全性。结果达比加群酯组及华法林组均无血栓栓塞及大出血并发症发生,而少量出血并发症的发生率与华法林相似,两组在血栓栓塞及出血并发症方面差异均无统计学意义(P>0.05)。与华法林组比较,达比加群酯组的D-二聚体水平减低[(0.25±0.16)mg/L vs(0.45±0.25)mg/L,P<0.05],术后住院时间减少[(3.05±0.32)d vs(7.27±0.25)d,P<0.05]。结论阵发性房颤射频消融术后应用达比加群酯是安全的。
Objective To investigate the safety of anticoagulant therapy of dabigatran etexilate after radiofrequency ablation of paroxysmal atrial fibrillation (AF). Methods Sixty patients with paroxysmal atrial fibrillation after radiofrequency catheter ablation were randomly divided into dabigatran etexilate group (n = 30) and warfarin group (n = 30). The anticoagulant therapy safety. Results There was no thromboembolism and major bleeding complications in dabigatran etexilate and warfarin groups, but the incidence of minor bleeding complications was similar to that in warfarin group. There was no statistical difference between the two groups in the incidence of thromboembolism and bleeding complications Significance (P> 0.05). D-dimer levels in dabigatran etexilate group were significantly lower than those in warfarin group [(0.25 ± 0.16) mg / L vs (0.45 ± 0.25) mg / L, P <0.05] [(3.05 ± 0.32) d vs (7.27 ± 0.25) d, P <0.05]. Conclusion The application of dabigatran etexilate after radiofrequency ablation of paroxysmal atrial fibrillation is safe.